Search results
Showing 2656 to 2670 of 8789 results
Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream (ESNM68)
Summary of the evidence on ivermectin 10 mg/g cream for treating papulopustular rosacea to inform local NHS planning and decision-making
Restless legs syndrome: Oxycodone/naloxone prolonged release (ESNM67)
Summary of the evidence on oxycodone/naloxone prolonged release for treating restless leg syndrome (RLS) to inform local NHS planning and decision-making
Promoting tolerance of enteral feeds in children and young people: domperidone (ESUOM18)
Summary of the evidence on domperidone to promote tolerance of enteral feeds in children and young people..
Summary of the evidence on dapoxetine for premature ejaculation to inform local NHS planning and decision-making
Chronic anal fissure: 0.2% topical glyceryl trinitrate ointment (ESUOM7)
Summary of the evidence on 0.2% topical glyceryl trinitrate ointment for chronic anal fissure to inform local NHS planning and decision-making
Opioid dependence: buprenorphine prolonged-release injection (Buvidal) (ES19)
Summary of the evidence on buprenorphine prolonged-release subcutaneous injection (Buvidal) for opioid dependence to inform local NHS
Summary of the evidence on oxybutynin for treating hyperhidrosis (excessive sweating) to inform local NHS planning and decision-making
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
Summary of the evidence on ramipril for relieving the symptoms of peripheral arterial disease (PAD) to inform local NHS planning and decision-making
Facial erythema of rosacea: brimonidine tartrate gel (ESNM43)
Summary of the evidence on brimonidine tartrate gel for treating facial erythema of rosacea to inform local NHS planning and decision-making
Summary of the evidence on sildenafil for managing digital ulcers to inform local NHS planning and decision-making
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Summary of the evidence on oral magnesium glycerophosphate for preventing recurrent hypomagnesaemia to inform local NHS planning and decision-making
Summary of the evidence on rituximab for treating autoimmune haemolytic anaemia (AIHA) to inform local NHS planning and decision-making
Immune (idiopathic) thrombocytopenic purpura: rituximab (ESUOM35)
Summary of the evidence on rituximab for immune (idiopathic) thrombocytopenic purpura in adults to inform local NHS planning and decision-making